Notable Reporting: Today bluebird bio Inc Stock Crashes

Notable Reporting: Today bluebird bio Inc Stock Crashes

The stock of bluebird bio Inc (NASDAQ:BLUE) is a huge mover today! The stock decreased 6.29% or $4.05 during the last trading session, hitting $60.35. About 1.86 million shares traded hands or 43.08% up from the average. bluebird bio Inc (NASDAQ:BLUE) has risen 39.06% since April 27, 2016 and is uptrending. It has outperformed by 33.84% the S&P500.
The move comes after 9 months negative chart setup for the $2.39 billion company. It was reported on Nov, 30 by Barchart.com. We have $58.54 PT which if reached, will make NASDAQ:BLUE worth $71.70M less.

Analysts await bluebird bio Inc (NASDAQ:BLUE) to report earnings on February, 22. They expect $-1.84 EPS, down 42.64% or $0.55 from last year’s $-1.29 per share. After $-2.07 actual EPS reported by bluebird bio Inc for the previous quarter, Wall Street now forecasts -11.11% EPS growth.

bluebird bio Inc (NASDAQ:BLUE) Ratings Coverage

Out of 14 analysts covering bluebird bio (NASDAQ:BLUE), 10 rate it a “Buy”, 1 “Sell”, while 3 “Hold”. This means 71% are positive. bluebird bio has been the topic of 29 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The stock of bluebird bio Inc (NASDAQ:BLUE) has “Buy” rating given on Thursday, December 3 by Roth Capital. The firm has “Outperform” rating given on Tuesday, October 20 by Oppenheimer. The company was upgraded on Monday, October 5 by Morgan Stanley. Cantor Fitzgerald initiated the stock with “Hold” rating in Friday, June 3 report. The firm has “Buy” rating given on Tuesday, August 11 by Zacks. Roth Capital maintained bluebird bio Inc (NASDAQ:BLUE) on Saturday, August 15 with “Buy” rating. The company was initiated on Thursday, September 22 by Roth Capital. The firm has “Equal-Weight” rating by Morgan Stanley given on Monday, December 7. Goldman Sachs initiated the stock with “Buy” rating in Wednesday, November 18 report. The firm earned “Neutral” rating on Monday, December 7 by Bank of America.

According to Zacks Investment Research, “Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio, Inc. is headquartered in Cambridge, Massachusetts.”

Insitutional Activity: The institutional sentiment increased to 1.48 in Q2 2016. Its up 0.48, from 1 in 2016Q1. The ratio is positive, as 29 funds sold all bluebird bio Inc shares owned while 52 reduced positions. 20 funds bought stakes while 61 increased positions. They now own 42.29 million shares or 3.30% more from 40.94 million shares in 2016Q1.
Creative Planning holds 25,801 shares or 0.01% of its portfolio. Orbimed Advsr Limited Liability has 1.19 million shares for 0.54% of their US portfolio. Moreover, Da Davidson And Company has 0% invested in bluebird bio Inc (NASDAQ:BLUE) for 900 shares. Pictet Asset Management Limited reported 28,897 shares or 0.01% of all its holdings. Barclays Public Ltd Com holds 0% of its portfolio in bluebird bio Inc (NASDAQ:BLUE) for 1,390 shares. Balyasny Asset Management Limited Co accumulated 225,167 shares or 0.06% of the stock. Sei Invests Co reported 1,217 shares or 0% of all its holdings. Dafna Cap Mgmt Limited Liability Corp has invested 0.41% of its portfolio in bluebird bio Inc (NASDAQ:BLUE). Schwab Charles Inv Management Incorporated owns 145,569 shares or 0.01% of their US portfolio. Deerfield Mngmt last reported 0.58% of its portfolio in the stock. Brighton Jones Ltd accumulated 0.32% or 42,371 shares. Ubs Asset Americas accumulated 145,991 shares or 0.01% of the stock. Moreover, Ny State Common Retirement Fund has 0.01% invested in bluebird bio Inc (NASDAQ:BLUE) for 168,000 shares. Artal Group last reported 450,000 shares in the company. Bnp Paribas Arbitrage Sa holds 0% of its portfolio in bluebird bio Inc (NASDAQ:BLUE) for 1,465 shares.

More recent bluebird bio Inc (NASDAQ:BLUE) news were published by: Fool.com which released: “Why bluebird bio Inc. Got Knocked Down Today” on November 03, 2016. Also Fool.com published the news titled: “Why bluebird bio Inc. Stock Jumped Today” on November 14, 2016. Fool.com‘s news article titled: “Why bluebird bio, Inc. Stock Got Crushed in October” with publication date: November 10, 2016 was also an interesting one.

BLUE Company Profile

bluebird bio, Inc., incorporated on April 16, 1992, is a biotechnology company. The Firm is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell immunotherapy. With its lentiviral gene therapies, T cell immunotherapy expertise and gene editing capabilities, it offers an integrated product platform with application in severe genetic and rare diseases, and in oncology. The Company’s gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder. The Company’s oncology programs are built using lentiviral gene delivery and T cell engineering, with a focus on developing T cell immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. The Company’s oncology program, bb2121, is a CAR T cell product candidate targeting B-cell maturation antigen, or BCMA, in multiple myeloma. It also offers discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment